Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
Antibiotic showdown: can tigecycline match older drugs against tough skin infections?
Cure CompletedThis trial compares the antibiotic tigecycline with two older antibiotics, ampicillin-sulbactam and amoxicillin-clavulanate, in adults with complicated skin or skin structure infections that need intravenous treatment. About 550 participants receive one of the treatments for 4 to…
Phase 4 • Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
New infant vaccine targets 13 strains of pneumonia bacteria
Vaccine CompletedResearchers are testing whether a 13-valent pneumococcal conjugate vaccine is safe and prompts a strong immune response in healthy infants in India. The trial enrolls 708 infants who receive the vaccine or an older seven-strain version alongside their routine childhood shots. The…
Phase 3 • Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer • Aim: Vaccine
Last updated Sep 21, 2026 17:00 UTC